The double-blind, placebo-controlled EMPACT-MI trial (NCT04509674) evaluated patients receiving empagliflozin (n=3,260) or placebo (n=3,262) for cardiovascular (CV) outcomes after acute myocardial infarction (MI). Over 17.9 months, the primary endpoint—hospitalisation for HF (HF) or death from any cause—occurred in 8.2% of the empagliflozin group and 9.1% of the placebo group, showing no significant difference (HR 0.90; […]